Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Common Equity (2019 - 2025)

Vivos Therapeutics has reported Common Equity over the past 7 years, most recently at -$1.5 million for Q4 2025.

  • Quarterly Common Equity fell 119.49% to -$1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.5 million through Dec 2025, down 119.49% year-over-year, with the annual reading at -$1.5 million for FY2025, 119.49% down from the prior year.
  • Common Equity was -$1.5 million for Q4 2025 at Vivos Therapeutics, down from $2.5 million in the prior quarter.
  • Over five years, Common Equity peaked at $36.5 million in Q2 2021 and troughed at -$1.5 million in Q4 2025.
  • The 5-year median for Common Equity is $6.7 million (2023), against an average of $10.1 million.
  • Year-over-year, Common Equity soared 16563.04% in 2024 and then tumbled 119.49% in 2025.
  • A 5-year view of Common Equity shows it stood at $25.5 million in 2021, then tumbled by 81.2% to $4.8 million in 2022, then tumbled by 91.44% to $411000.0 in 2023, then soared by 1835.28% to $8.0 million in 2024, then plummeted by 119.49% to -$1.5 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Common Equity are -$1.5 million (Q4 2025), $2.5 million (Q3 2025), and $4.6 million (Q2 2025).